Lawmakers Push Tougher China Biopharma Restrictions
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Congress passed a bill last year restricting how U.S. pharmaceutical and biotechnology companies can do business with Chinese firms.
- U.S. lawmakers are already laying the groundwork for additional legislative and regulatory measures to counter the rise of Chinese biopharma companies.
- Federal health officials are simultaneously working to make it easier for companies to operate in the U.S., pairing tougher Chinese-facing rules with domestic easing.
- Bobby McMillin, partner at Arnold Porter, said of the existing restrictions: "The itch has not been entirely scratched."
Why it matters: The simultaneous tightening of restrictions on Chinese biopharma and loosening of operating rules for U.S. firms reveals a competitive-protection strategy rather than a pure national-security measure, positioning domestic pharma to capture share as Chinese partnerships become harder to maintain, per Bobby McMillin.
